Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease.

Exa-cel therapy achieved transfusion independence or absence of severe vaso-occlusive crises in children aged 5 to 11 with transfusion-dependent β-thalassemia or sickle cell disease, respectively, over 16 months.

• Why it matters: This work addresses the critical need for effective, durable treatments for young children with these severe blood disorders, where current options are limited and often invasive or ineffective.
• What they did: Researchers conducted two phase 3, open-label studies involving 15 children with β-thalassemia and 11 with sickle cell disease, administering exa-cel after myeloablative conditioning and monitoring outcomes for at least 16 months.
• The result: All children followed for at least 16 months became transfusion independent or free from vaso-occlusive crises, though all experienced serious adverse events, highlighting both the therapy's promise and risks.